Keltican hard capsules blister No. 30

Instructions for Keltican hard capsules blister No. 30

Composition

active substances: sutidine-5'-disodium monophosphate, (CMP disodium salt), uridine-5'-trisodium triphosphate (UTP trisodium salt), uridine-5'-disodium diphosphate (UDP disodium salt), Uridine-5'-disodium monophosphate (UMP disodium salt);

1 capsule contains cytidine-5'-disodium monophosphate 5.0 mg; uridine-5'-trisodium triphosphate, uridine-5'-disodium diphosphate, uridine-5'-disodium monophosphate – a total of 3.0 mg (equivalent to 1.330 mg of uridine);

excipients: citric acid monohydrate; sodium citrate; magnesium stearate; colloidal anhydrous silicon dioxide; mannitol (E 421);

capsule shell: capsule body: black iron oxide (E 172); titanium dioxide (E 171); gelatin; capsule cap: indigo carmine; titanium dioxide (E 171); gelatin.

Dosage form

The capsules are hard.

Main physicochemical properties: capsules (No. 2) with a blue cap and a gray body, containing a white hygroscopic powder.

Pharmacotherapeutic group

Drugs used in diseases of the nervous system. ATX code N07X X.

Pharmacological properties

The activity of the drug Keltikan is provided by phosphate groups, which are necessary for the combination of monosaccharides with ceramides to form cerebrosides and phosphatidic acids, which are the basis of sphingomyelin and glycerophospholipids. Sphingomyelin and glycerophospholipids are the main components of the myelin sheath. Thus, when using the drug Keltikan, an increase in trophic properties for the maturation and regeneration of axons of nervous tissue is achieved.

Indication

Treatment of neuropathies of osteoarticular origin (sciatica, radiculitis), metabolic (alcoholic, diabetic polyneuropathy), infectious origin (shingles). Facial neuralgia, trigeminal neuralgia, intercostal neuralgia, lumbago.

Contraindication

Hypersensitivity to the components of the drug.

Interaction with other medicinal products and other types of interactions

Not installed.

Application features

Taking Keltican is not related to food intake. Therefore, the drug can be taken before, during, or after meals.

Keltican contains mannitol, which may have a mild laxative effect. If you have stomach upset, it is recommended to take Keltican with food.

Use during pregnancy or breastfeeding

The safety of the drug Keltican during pregnancy and breastfeeding has not been established. Pregnant women or women who may become pregnant, or during breastfeeding, Keltican should be used only if the expected therapeutic benefit outweighs any possible risk to the fetus/child.

Ability to influence reaction speed when driving vehicles or other mechanisms

Keltican does not affect the ability to drive vehicles and other complex mechanisms.

Method of administration and doses

The drug should be taken orally, regardless of meals.

Adults: recommended dose – 1 capsule 3 times a day.

The duration of the course of treatment is determined by the doctor individually.

Children

The drug should not be used in children.

Overdose

Given the low toxicity of the drug, the likelihood of poisoning is very low even if the therapeutic dose is accidentally exceeded.

In case of overdose, symptomatic treatment is necessary.

Side effects

Not described. However, hypersensitivity reactions are possible.

Expiration date

2 years.

Storage conditions

Store at a temperature not exceeding 30 ° C. Keep out of the reach of children!

Packaging

15 capsules in a blister; 2 blisters in a cardboard box.

Vacation category

According to the recipe.

Producer

Ferrer Internacional, SA, Spain.

Address

Joan Buscalla, 1-9, Sant Cugat del Valles, 08173 Barcelona, Spain/ Joan Buscalla, 1-9, Sant Cugat del Valles, 08173 Barcelona, Spain.